About Us

We are SK Life Science,
a CNS-focused pharmaceutical company

Values define us

At SK Life Science, Inc. (SKLSI), we aim to embody our core values. They are what you can expect from us.

Our purpose

We believe there is more to life when you connect health with happiness.

  • Empower excellence

  • Be fully engaged

  • Appreciate
    recognize people

  • Embody a pioneering spirit

  • Always do the right thing

  • Inspire happiness!

Our purpose

We believe there is more to life when you connect health with happiness.

Tireless in our commitment to the CNS community


We are proud to be the first Korea-based company to discover, develop and commercialize a molecule from inception through FDA approval without partnering or out-licensing


We have 30 years of experience in R&D and are dedicated to changing the status quo in CNS


We currently have 8 compounds in the clinical development pipeline

SK Life Science: a history of discovery

SK Life Science is a subsidiary of SK Biopharmaceuticals, focused on developing innovative, next-generation drugs. Both are a part of SK Group, a global conglomerate headquartered in Korea.

Select a year



A global presence

SK Life Science is a subsidiary of SK Biopharmaceuticals, Co., Ltd., and a part of SK Group—a large conglomerate global corporation

Our parent company’s global reach
Learn about our global headquarters
Paramus, NJ USA

Our focus

Commercialization of meaningful CNS products in the US


See bio

See less


Donghoon Lee

President &
Chief Executive Officer

Mr. Donghoon Lee is the Chief Executive Officer and President of SK Biopharmaceuticals and its U.S. subsidiary SK Life Science. His vision is to transform SK Biopharmaceuticals and SK Life Science into a leading global healthcare company, while generating synergy with SK Group, its affiliates, and partners.

Previously, Mr. Lee was the Executive Vice President and Head of Bio Investment Center of SK Inc. where he executed key investment deals in line with SK Group’s vision to fortify a variety of business units as its main growth drivers.

He spearheaded SK’s global deals such as launching a U.S. joint venture called ProteoVant, with Switzerland-based Roivant Sciences; acquiring France-based Yposkesi, a CDMO for cell and gene therapies; and making investments in the Center for Breakthrough Medicines.

Mr. Lee previously held leadership positions at the global professional services firm, KPMG, and pharmaceutical companies, including as the CEO and Executive Vice President of Dong-A Socio Holdings.

Mr. Lee was educated at Seoul National University and at Ohio State University where he received his MBA in Finance and Accounting.

SK Group: key facts


Second largest
conglomerate in
Korea (2021)1


Founded in 1953

119 B

$119 billion in revenue


#97 by revenue on the
Fortune Global 500
list of companies3


Number of global
partners and affiliates2

Select a year for details



Our goal

Become a global leader in CNS by unlocking the complex mysteries of the brain


Pushing innovation forward together Want to collaborate with us?

Because more can be done when people come together, we seek partnerships with universities, government organizations, and pharmaceutical and biotech companies across multiple therapeutic areas.

Select a disorder for details


Ethics & Compliance Program

SK Life Science, Inc. (SKLSI) is committed to conducting business honestly, ethically, and in compliance with laws and regulations. Our goal is to conduct business and promote our products in an informed, compliant manner. Our program is tailored to meet the standards set forth by the Office of Inspector General (OIG) for the U.S. Department of Health and Human Services in its Compliance Program Guidance for Pharmaceutical Manufacturers, as well as other relevant industry guidance and laws.

The SKLSI Compliance and Ethics Hotline offers employees, business partners, customers, and members of the public the opportunity to report concerns about potential misconduct or unethical behavior. To submit a question or concern, please contact our anonymous hotline at 833-490-0007, or visit www.lighthhouse-services.com/sklsi or SK Whistleblowing Portal https://ethics.sk.co.kr.

SKLSI Code of Conduct > Vendor and Supplier Code of Conduct >

CA Annual Declaration of Compliance

SK Life Science, Inc. (SKLSI) has a Comprehensive Compliance Program (CCP) in accordance with the requirements set forth by California Health & Safety Code §§ 119400-119402.    To view SKLSI’s declaration of compliance, click the link below:

SKLSI California Compliance Declaration >

Anti-Bribery and Anti-Corruption Policy

SK Life Science, Inc. (SKLSI) has a policy that establishes the requirement for SKLSI Associates to conduct all business ethically and in accordance with all applicable anti-bribery and anti-corruption (ABAC) laws and regulations in the jurisdictions in which SKLSI does business.

Anti-Bribery and Anti-Corruption Policy >

References: 1. https://www.koreaherald.com/view.php?ud=20220209000131. Accessed April 2022 2.Data on file, SK Life Science. 3. Fortune Global 500 list for 2020. Fortune 500 Web site. http://fortune.com/global500/list/. Accessed May 13, 2021. 4.Zack MM, Kobau R. National and state estimates of the numbers of adults and children with active epilepsy—United States, 2015. MMWR Morb Mortal Wkly Rep. 2017;66(31):821-825. 5.Centers for Disease Control and Prevention (CDC). At A Glance 2017: Epilepsy: one of the nation’s most common neurological conditions. www.cdc.gov/chronicdisease/resources/publications/aag/epilepsy.htm. Accessed October 8, 2018. 6.American Academy of Sleep Medicine. Rising prevalence of sleep apnea in U.S. threatens public health. https://aasm.org/rising-prevalence-of-sleep-apnea-in-u-s-threatens-public-health/. Published September 29, 2014. Accessed October 8, 2018. 7.Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol. 2013;177(9):1006-1014. 8.Yawn BP, Wollan PC, Weingarten TN, et al. The prevalence of neuropathic pain: clinical evaluation compared with screening tools in a community population. Pain Med. 2009;10(3):586-593. 9.Schaefer C, Mann R, Sadosky A, et al. Burden of illness associated with peripheral and central neuropathic pain among adults seeking treatment in the United States: a patient-centered evaluation. Pain Med. 2014;15(12):2105-2119. 10.Alzheimer’s Association. 2017 Alzheimer’s disease facts and figures. Alzheimers Dement. 2017;13(4):325-373. 11.Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication [published correction appears in Arch Gen Psychiatry. 2005;62(7):709]. Arch Gen Psychiatry. 2005;62(6):617-627. 12.Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593-602. 13.Greenberg PE, Fournier A-A, Sisitsky T, Pike CT, Kessler RC. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015;76(2):155-162. 14.Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002 [abstract]. J Clin Psychiatry. 2005;66(9):1122-1129. 15.National Institute of Mental Health. Any anxiety disorder among adults. https://www.nimh.nih.gov/health/statistics/prevalence/any-anxiety-disorder-among-adults.shtml. Accessed October 8, 2018. 16.Howden LM, Meyer JA. Age and sex composition: 2010. US Census Bureau Web site, 2010 Census Briefs. https://www.census.gov/prod/cen2010/briefs/c2010br-03.pdf. Accessed October 8, 2018.

Back to Top